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ABSTRACT
Chemo-resistance is a clinical barrier to more effective anti-cancer therapy. In 
this context, cancer stem-like cells (CSCs) are thought to be chemo-resistant, resulting 
in tumor recurrence and distant metastasis. Our hypothesis is that chemo-resistance 
in CSCs is driven, in part, by enhanced mitochondrial function. Here, we used breast 
cell lines and metastatic breast cancer patient samples to begin to dissect the role 
of mitochondrial metabolism in conferring the CSC phenotype. More specifically, we 
employed fluorescent staining with MitoTracker (MT) to metabolically fractionate 
these cell lines into mito-high and mito-low sub-populations, by flow-cytometry. 
Interestingly, cells with high mitochondrial mass (mito-high) were specifically 
enriched in a number of known CSC markers, such as aldehyde dehydrogenase 
(ALDH) activity, and they were ESA+/CD24-/low and formed mammospheres with 
higher efficiency. Large cell size is another independent characteristic of the stem 
cell phenotype; here, we observed a >2-fold increase in mitochondrial mass in large 
cells (>12-μm), relative to the smaller cell population (4–8-μm). Moreover, the mito-
high cell population showed a 2.4-fold enrichment in tumor-initiating cell activity, 
based on limiting dilution assays in murine xenografts. Importantly, primary human 
breast CSCs isolated from patients with metastatic breast cancer or a patient derived 
xenograft (PDX) also showed the co-enrichment of ALDH activity and mitochondrial 
mass. Most significantly, our investigations demonstrated that mito-high cells were 
resistant to paclitaxel, resulting in little or no DNA damage, as measured using the 
comet assay. In summary, increased mitochondrial mass in a sub-population of breast 
cancer cells confers a stem-like phenotype and chemo-resistance. As such, our current 
findings have important clinical implications for over-coming drug resistance, by 
therapeutically targeting the mito-high CSC population.
INTRODUCTION
Cancer stem-like cells (CSCs) or tumor-initiating 
cells (TICs) are thought to be responsible for driving 
patient relapse (tumor recurrence and metastasis), as 
a consequence of their chemo-resistance and/or radio-
resistance [1–6]. However, the cellular mechanism(s) 
driving this drug-resistant phenotype remain largely 
unknown. Elucidation of the mechanisms underpinning 
drug-resistance would have broad clinical implications, for 
the prevention of treatment failure in a variety of different 
cancer types.
One hypothesis is that mitochondria are involved 
in conferring drug-resistance, as they control both 
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i) energy metabolism and ii) susceptibility towards 
apoptotic cell death. Previous studies have shown that 
catabolic cancer-associated fibroblasts (CAFs) produce 
mitochondrial fuels (such as L-lactate, ketone bodies 
and L-glutamine), which are sufficient to confer a drug-
resistant phenotype in MCF7 breast cancer cells in 
culture [7, 8]. In this context, treatment with metformin 
(a mitochondrial inhibitor of Complex I) was sufficient 
to revert this drug-resistance phenotype. Similar results 
were also obtained in a variety of distinct patient cohorts 
followed at the MD Anderson and Dana-Farber Cancer 
Centers, showing that increased mitochondrial integrity 
(in stained tumor-tissue sections) was associated with 
drug-resistance and treatment failure in a number of 
different cancer types, including multiple myeloma, 
acute myelogenous and lymphoblastic leukemia, as well 
as ovarian cancers [9, 10].
Our group has previously shown that breast 
CSCs are chemo- and radio-resistant and that stem 
cell regulatory pathways, such as Notch, Wnt, FAK 
and CXCR1/2, may play a role in their maintenance 
and resistance mechanisms [11–17]. However, there 
is a limited understanding of the metabolic activities 
within CSC-enriched and CSC-depleted populations, 
although mechanistic differences are undoubtedly 
present [18–20]. Metabolic investigations in glioma stem 
cells (GSCs) showed that radio-resistant GSCs were less 
glycolytic, with a higher mitochondrial reserve capacity 
[18], indicating that specific inhibition of OXPHOS may 
target the GSCs. Similarly CSCs isolated from ovarian 
cancer patients also showed evidence of a metabolic 
profile dominated by OXPHOS, even in the absence of 
glucose. The authors suggest that these findings could 
be instrumental in helping CSCs to escape damage in 
hypo-oxygenated tumor areas [21].
To determine if breast CSC characteristics were 
associated with a specific metabolic activity, we used 
MitoTracker (MT) as an investigational tool to live-
stain and metabolically fractionate cancer cell lines 
and patient samples into mito-high and mito-low cell 
populations. Our study demonstrates that cells with high 
mitochondrial mass showed many of the characteristics 
of CSCs, including increased ALDH activity, 
mammosphere formation activity and tumor initiation 
in vivo. In addition, we show increased survival and 
decreased DNA damage within the mito-high cells after 
paclitaxel treatment, suggesting that mitochondrial mass 
confers a chemo-resistance phenotype, as predicted.
Thus, our current findings provide a new 
mitochondrially-based model for understanding the 
relationship between CSCs and chemo-resistance. As this 
approach is technically simple, it could be used to rapidly 
isolate chemo-resistant CSC populations from possibly 
any tumor type, facilitating the development of new 
classes of drugs to target chemo-resistance.
RESULTS
High mitochondrial mass directly correlates 
with ALDH activity, the ESA+CD24-/low CSC 
population and larger cell size
Studies show CSC and non-CSC populations 
may use different metabolic pathways and this may 
contribute to their increased survival and resistance 
to chemotherapy [18, 22, 23]. To determine if 
mitochondrial mass is increased within the CSC 
population, we fluorescently-labeled mitochondria 
in MCF7 and MDA MB 231 breast cancer cells with 
MitoTracker Deep-Red. These cells were co-stained 
with ALDEFLUOR or CSC cell surface markers ESA/
CD24, to identify the CSC population. Both ALDH+ and 
ESA+/CD24- cell populations have been shown to be 
enriched in mammosphere- and tumor-initiating cells, 
key characteristics of CSCs [2, 24–28].
Figure 1A, 1B, 1C shows that MitoTracker staining 
is specifically enriched in the ALDH+ cell population of 
MCF7 and MDA MB 231 cells (P < 0.05). A similar fold 
increase in MitoTracker mean fluorescence intensity was 
also observed in the ESA+CD24-/low CSC population of 
the MDA MB 231 cell line (Figure 1D, P < 0.01). These 
findings suggest that CSCs contain a higher mitochondrial 
mass than the non-CSC population.
As an alternative approach to enrich CSCs, we 
used cell size. Previous studies have shown that cells 
with mammary stem cell activity tend to be larger than 
10 μm [29]. As a consequence, we used forward scatter 
(FSC) to isolate three different cell populations, based 
solely on size: 4–8 μm, 9–12 μm and >12 μm (Figure 
2A). Quantitative analysis of MitoTracker staining 
demonstrated that larger cells were associated with 
significantly higher mitochondrial mass, up to 2.5-fold, 
consistent with an anabolic CSC phenotype (Figure 2B 
and 2C, P < 0.001).
These data indicate that high mitochondrial mass, 
as determined by MitoTracker staining, is associated with 
breast CSC populations enriched via three independent 
CSC markers, namely ALDH activity, ESA/CD24 cell 
surface levels or cell size.
High mitochondrial mass directly correlates with 
ALDH activity in primary breast cancer cells 
isolated from metastatic disease sites or a patient 
derived xenograft (PDX)
To validate the possible in vivo relevance of our 
above findings, we next examined mitochondrial mass in 
primary CSC populations from metastatic breast cancer 
patients. For this purpose, we co-labeled breast cancer 
cells isolated directly from pleural effusions or ascites 
fluids (n = 4) with ALDEFLUOR and MitoTracker.
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Figure 3A, 3B, and 3D supports our breast cancer 
cell line data, showing that ALDH+ primary metastatic 
breast CSCs have significantly higher mitochondrial mass 
than the ALDH- cells (P < 0.05). Notably, although these 
findings are of a low sample size, our results appear to 
be independent of estrogen receptor (ER), progesterone 
(PR) and HER2 status (Figure 3F). In addition, we also 
show similar results within the ALDH+ population of 
human breast cancer cells isolated from a patient derived 
xenograft (BB3RC50*) (Figure 3C and 3E). These data 
suggest that high mitochondrial mass is associated with 
CSC populations from freshly isolated metastatic breast 
cancer cells.
High mitochondrial mass enriches for 
mammosphere-forming activity in vitro 
and tumor-initiating activity in vivo
Although we correlated high mitochondrial mass 
with a number of CSC markers, it was important to validate 
our findings with more functional parameters, such as 
mammosphere-forming activity and tumor initiation, 
that have been traditionally associated with “stemness” 
[30–32]. MCF7 and MDA MD 231 cells were sorted into 
mito-high (top 5% of cells with high MitoTracker staining) 
and mito-low (bottom 5% of cells with low MitoTracker 
staining) cell populations using flow-cytometry. The 
mito-high and mito-low cell populations were then seeded 
under non-adherent culture conditions and the number 
of mammospheres >60 μm were counted after 5 days. 
Both MCF7 and MDA MB 231 cells showed a significant 
2- to -3 fold increase in mammosphere forming efficiency 
within the mito-high population, compared to mito-low 
cells (Figure 4A, P < 0.01).
The most stringent test of CSC activity is the 
capacity for tumor initiation [31, 32]. Serial dilutions of 
MDA MB 231 mito-high and mito-low cells (1, 5, 10, 
and 50 cells) were injected into NOD scid gamma (NSG) 
mice, and tumor initiation and growth were measured 
over 9 weeks. Our results show high mitochondrial 
mass was not associated with increased tumor growth/
size (Figure 4B). However, using extreme limiting 
dilution analysis (ELDA), we demonstrate a 2.4-fold 
increase in tumor initiation cell frequency within the 
mito-high population of MDA MB 231 cells, when 
compared to mito-low (Figure 4C, P < 0.05). Although 
high mitochondrial mass was not associated with 
increased tumor size (Figure 4B), these data show 
that high mitochondrial mass is specifically associated 
with two key functional CSC characteristics, in vitro 
mammosphere formation and tumor-initiating cell 
frequency in vivo.
Figure 1: Mitochondrial mass directly correlates with ALDH activity and the ESA+CD24-/low CSC 
population. Representative dot plots of ALDH activity in MDA MB 231 A. and MCF7 B. cells, showing ALDH+ and ALDH- cells in the 
absence of DEAB. Histograms represent typical staining intensity of MitoTracker in ALDH+ and ALDH- populations in both cell lines. C. Graph 
showing fold change in mean fluorescence intensity (MFI) of MitoTracker (Deep Red; 640 nM), within ALDH+ and ALDH- populations 
of MCF7 and MDA MB 231 cell lines (n = 4 independent experiments). D. Graph showing fold change in mean fluorescence intensity of 
MitoTracker (Deep Red; 640 nM) within the ESA+CD24- (cancer stem-like cell, CSC) population and ESA+/CD24- depleted (non-CSC) 
populations of MDA MB 231 cells (n = 4 independent experiments). Bar graphs are shown as the mean ± SEM, t-test, two-tailed test, *P ≤ 0.05, 
**P ≤ 0.01.
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CSCs with high mitochondrial mass 
preferentially survive paclitaxel treatment and 
show reduced DNA strand breaks, conferring 
chemo-resistance
Another key CSC characteristic is resistance to 
radio- and chemo-therapy [2, 3, 17]. In order to correlate 
chemo-resistance with mitochondrial mass, MCF7 and 
MDA MB 231 cells were first separated into mito-high 
and mito-low cell fractions by flow-cytometry, using 
MitoTracker. The two cell populations were then seeded 
into mammosphere culture in the presence or absence 
of paclitaxel (0.1–0.5 μM) to assess their survival 
characteristics and susceptibility towards DNA damage.
Figure 5A and 5B shows that cells with high 
mitochondrial mass are resistant to paclitaxel, 
demonstrating little or no decrease in mammosphere 
formation, compared to vehicle alone controls. In contrast, 
cells with low mitochondrial mass show significant 
reductions in mammosphere formation, up to 2-fold, at the 
same concentrations (P < 0.001). Thus, high mitochondrial 
mass directly correlates with resistance to paclitaxel 
in CSCs.
To better mechanistically understand this 
chemo-resistance phenotype, we used the comet assay 
to functionally measure the levels of DNA strand breaks 
after 24 h of paclitaxel treatment [33]. Remarkably, 
Figure 5C and 5D shows that cells with high mitochondrial 
mass have significantly reduced DNA damage, whereas 
cells with low mitochondrial mass are more chemo-
sensitive, with increased comet tail length after paclitaxel 
treatment. These data indicate that high mitochondrial 
mass allows CSCs to survive chemotherapy, by affording 
protection or increased repair against DNA damage.
DISCUSSION
Drug resistance is a rate-limiting barrier to 
successful cancer therapy. Tumor-initiating cells and/or 
CSCs share a common chemo-resistant phenotype, which 
ultimately drives tumor recurrence and metastatic disease, 
resulting in patient relapse [1–6]. In this report, we show 
that high mitochondrial mass is associated with CSC 
markers, functional CSC characteristics (mammosphere 
and tumor initiation) and chemo-resistance. Our findings 
highlight the need to further understand and target the 
Figure 2: Mitochondrial mass directly correlates with the enriched breast CSC population, identified using large cell 
size. A. Typical dot plot showing side scatter (SSC) and forward scatter (FSC) of live breast cancer cells, gates represent cell size (RED- 
4–8 μm; BLUE- 9–12 μm; BLACK > 12 μm; [29]). Histograms show MitoTracker mean fluorescence intensity within the 3 cell size groups 
of MDA MB 231 and MCF7 cells. Graphs showing fold change in the mean fluorescence intensity (MFI) of MDA MB 231 B. and MCF7s 
C. within the 9–12 μm and > 12 μm cell size compared to the smallest cells (4–8 μm), n = 3 independent experiments, 2 technical replicates. 
Bar graphs are shown as the mean ± SEM, t-test, two-tailed test, ***P < 0.001.
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metabolic pathways in CSCs, to improve clinical outcome 
in breast cancer patients.
ALDEFLUOR is an investigational tool, which is 
routinely used to measure ALDH activity in cell lines 
and primary tumor samples, enriching for CSC activity 
via flow-cytometry [27, 28]. However, the ALDH gene 
family is quite large and it still remains controversial 
which ALDH isoforms contribute towards ALDH activity 
that is associated with CSC activity [34–37]. As our 
current report shows that ALDH activity in CSCs is also 
associated with high levels of mitochondrial mass, in cell 
lines and patient samples, it is quite possible that this stem-
cell associated ALDH activity may also be derived from 
mitochondria. In fact, at least 7 members of the ALDH 
family of genes are known to be targeted to mitochondria 
and are bonafide resident mitochondrial proteins, 
including ALDH2, ALDH1L2, ALDH4A1, ALDH5A1, 
ALDH6A1, ALDH7A1 and ALDH18A1. Therefore, this 
new mitochondrial connection could functionally explain 
the relationship between ALDH activity and stemness in 
cancer cells. In support of this idea, it was recently shown 
that the drug-resistant ALDH-high cell sub-population has 
significantly increased mitochondrial respiration, leading 
to increased levels of oxidative stress [38].
We also showed that other CSC markers (ESA/
CD24), and large cell size were associated with high 
mitochondrial mass. This supports other published studies 
where breast CSCs have been shown to have a higher 
Figure 3: Mitochondrial mass correlates with ALDH activity in primary breast cancer cells isolated from metastatic 
breast cancer samples and a patient derived xenograft. Representative dot plots of ALDH activity in primary metastatic breast 
cancer samples BB3RC88 A. BB3RC84 B. and patient derived xenograft sample (BB3RC50) C. cells showing ALDH+ and ALDH- cells in 
the absence of DEAB. Histograms represent typical staining intensity of MitoTracker (MT) in ALDH+ and ALDH- populations. D. Graph 
showing fold change in mean fluorescence intensity (MFI) of MitoTracker (Deep Red; 640 nM) within ALDH+ and ALDH- populations 
of primary metastatic breast cancer samples (n = 4), BB3RC77, BB3RC79, BB3RC88, BB3RC84. E. Graph showing fold change in mean 
fluorescence intensity (MFI) of MitoTracker (Deep Red; 640 nM) within ALDH+ and ALDH- populations of a patient derived xenograft 
sample (BB3RC50). F. Table showing the original (invasive) breast cancer characteristics of the metastatic (MET) breast cancer samples. 
Estrogen receptor (ER) and progesterone receptor (PR) status, + = > 10% positive; HER2 status, + = 3+ or 2+ & amplified; BB3RC50* 
denotes the PDX sample. Bar graphs are shown as the mean ± SEM, t-test, two-tailed test, *P ≤ 0.05.
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maximum mitochondrial capacity and mitochondrial 
proton leak, compared to their differentiated non-CSC 
progeny [22]. Moreover, we demonstrated that cells 
with high mitochondrial mass were also functionally 
more stem-like, showing significant increases in 
i) mammosphere-forming efficiency and ii) tumor-
initiating cell activity in vivo. The mechanism behind 
the increased mitochondrial mass in our study remains 
unknown. However, CSC populations are known to have 
a distinct genomic and proteomic expression profile [39], 
which can contribute to the stem cell characteristics of 
CSCs. This differential expression may also influence 
mitochondrial biogenesis, for example high levels of 
mTORC1 and its activity are seen in CSC populations 
of pancreatic and breast cancer cells [40, 41]. Studies 
have shown mitochondrial activity and biogenesis are 
controlled by mTORC1 by promotion of the translation 
of mitochondria-related mRNAs, via inhibition of the 
eukaryotic translation initiation factor 4E (eIF4E)-
binding proteins [42], suggesting the high activity of 
mTORC1 in CSCs may increase mitochondrial biogenesis. 
Similarly, the transcription coactivator peroxisome 
proliferator-activated receptor gamma, coactivator 1 alpha 
(PGC-1α), a known mediator of mitochondrial biogenesis, 
has been shown to be overexpressed in circulating tumor 
cells (with CSC characteristics) from the MMTV-PyMT 
spontaneous mouse breast cancer model [43]. The over-
expression of oncogenes is also linked to increased 
mitochonidrial mass. Increased expression of Myc 
maintained the stemness of brain stem cells and glioma 
CSCs [44, 45] but also stimulated nuclear-encoded 
mitochondrial genes and mitochondrial biogenesis 
[46]. These studies suggest the differential expression 
of proteins and genes within the CSC population may 
preferentially favor increased mitochondrial biogenesis, 
compared to the non-CSC population.
The inherent expression of genes that increase 
mitochondrial biogenesis may, in turn, aid the maintenance 
of stem cell characteristics, as mitochondrial function 
has been shown to be important for the self renewal 
and differentiation capacity of stem cells. Although 
mitochondrial mass in embryonic stem cells is low, 
Figure 4: High mitochondrial mass is specifically associated with mammosphere formation and tumor-initiating 
activity. MDA MB 231 and MCF7 cells were subjected to flow-cytometry to isolate different populations of MitoTracker (MT) stained cells: 
mito-low = lowest 5% of MitoTracker stained cells; mito-high = highest 5% of MitoTracker stained cells. Mito-high and low populations 
were then seeded into mammosphere cultures A. or injected by limiting dilution into NOD scid gamma (NSG) mice B. (A) Graph showing 
fold change in mammosphere formation in mito-low and mito-high populations of MDA MB 231 and MCF7 cells, n = 4 independent 
experiments, ≥3 technical replicates. (B) Graph showing tumor size (mm3), 9 weeks after cell injections (sub-cutaneous), with 1, 5, 10 and 
50 cells per injection of mito-low and mito-high MDA MB 231 cell populations. Each dot represents a tumor, hollow dots <100 μm = no 
tumor initiation. C. Extreme limiting dilution analysis (ELDA) was used to calculate the tumor initiation cell frequency within the mito-low 
and mito-high MDA MB 231 cell populations. Graphs are shown as the mean ± SEM, t-test, two-tailed test, **P ≤ 0.01, **** ≤ 0.0001.
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studies in normal adult stem cells and CSCs demonstrate 
the levels of mitochondrial mass are tissue-specific [47]. 
In glioblastoma, the depletion of mitochondrial DNA, 
after 2′-3′-dideoxycytidine treatment, inhibited tumor 
initiation [48], whereas reduced mitochondrial mass 
identified lung cancer stem cells [49]. A recent paper 
also highlighted the asymmetric apportioning of old/aged 
mitochondria, where the retention of young mitochondria 
during asymmetric self-renewal was vital to maintaining 
the stem cell characteristics of normal mammary epithelial 
cells [50]. Our data suggests that increased mitochondrial 
mass may increase tumor initiation via increased self 
renewal. Further investigations on the tumor initiation 
capacity of breast CSCs after the depletion or inactivation 
of mitochondria are warranted to validate this hypothesis.
Although high mitochondrial mass increased 
tumor initiation, especially at low cell numbers, it did 
not significantly affect overall tumor growth/size. These 
findings may simply reflect the recent observation that 
tumor cells have the capacity to “steal” mitochondrial 
DNA (mt-DNA) from host stromal cells (such as 
mesenchymal stem cells or endothelial cells), to boost 
Figure 5: CSCs with high mitochondrial mass preferentially survive paclitaxel treatment and show reduced DNA 
strand breaks. MDA MB 231 and MCF7 cells were subjected to flow-cytometry to isolate different populations of MitoTracker stained 
cells: mito-low = lowest 5% of MitoTracker stained cells; mito-high = highest 5% of MitoTracker stained cells. Mito-high and low 
populations were then seeded into mammosphere culture in the presence or absence of paclitaxel (A–B) or treated with paclitaxel or control 
(DMSO 1:10,000) for 24 h before DNA damage analysis via a comet assay (C–D). A–B. Graphs show fold change in mammosphere 
formation in mito-low and mito-high cells (MDA MB 231 and MCF7), after treatment with 0.1 μM and 0.5 μM paclitaxel compared to 
vehicle alone controls, n = 3 independent experiments, ≥3 technical replicates. C–D. Graph shows fold change in comet tail length in mito-
low and mito-high cell populations (MDA MB 231 and MCF7), after 24 h of 0.5 μM paclitaxel treatment, the images show representative 
comet tails under all conditions. Bar graphs are shown as the mean ± SEM, (ANOVA) test with post-hoc dunetts multiple comparisons 
(A–B), t-test, two-tailed test (C–D), **P ≤ 0.01, **** ≤ 0.0001.
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their metabolic capacity towards OXPHOS, depending on 
the length of time they spend in the host [51]. Interestingly, 
it has also been reported that the transfer of stromal cell 
mitochondria to cancer cells increases their respiratory 
capacity and chemo-resistance [52].
Our findings also demonstrated that cells with 
high mitochondrial mass were resistant to chemotherapy, 
effectively protecting, delaying or avoiding DNA strand 
breaks after 24 h of paclitaxel treatment. Other studies 
show that inhibiting ALDH activity, which is increased 
within the mito-high population, can increase chemo-
sensitivity [53, 54], although the specific mechanism is 
currently unknown. Evidence also shows that chemo-
resistant solid cancers could be driven by numerous 
metabolic mechanisms, including reduced reactive oxygen 
species [55] and increased mitochondrial coupling [56]. 
Similarly, a recent study has identified that SIRT4, a 
mitochondria-localized sirtuin, regulates the metabolic 
responses to DNA damage by repressing mitochondrial 
glutamine metabolism. This contributes to the control of 
cell cycle progression and the maintenance of genomic 
integrity in response to DNA damage [57]. Differential 
metabolic control of the cell cycle may therefore play a 
role in reducing DNA damage in our study, as paclitaxel 
requires cell division to induce microtubule damage. 
Further exploration to elucidate the exact mechanisms is 
warranted.
CSCs are known to have increased DNA damage 
responses and repair mechanisms, characterized by 
the expression of high levels of DNA repair proteins, 
e.g. Chk1 and Rad51 [58, 59]. Since our mito-high cell 
population is enriched in established CSC markers, it is 
reasonable to presume the reduced DNA damage may 
be facilitated in part via non-metabolic mechanisms. 
However, recent studies have described signaling linking 
the metabolite fumarate to the promotion of DNA repair. 
Increased fumarate inhibited KDM2B histone demethylase 
activity, which subsequently increased accumulation of 
DNA-PK at double strand break regions, driving non-
homologous end-joining DNA repair and cell survival 
[60, 61]. Research to date has only just started to reveal 
the complex signaling cross-talk linking metabolic 
processes with the DNA damage response and other 
biological functions. Further investigations will aid our 
understanding and deliver new targets to improve cancer 
treatment.
Interestingly, most markers of stemness that 
are routinely used to enrich for CSC activity (CD24, 
Figure 6: Therapeutic targeting of chemo-resistant CSCs: A new systematic approach. Here, we propose a new clinical 
strategy for over-coming drug resistance. We suggest that primary or metastatic clinical samples could be used to purify chemo-resistant 
“mito-high” CSCs by flow-cytometry, after live-staining with MitoTracker, to estimate mitochondrial mass. Then, these chemo-
resistant CSCs would be subjected to phenotypic drug screening, with well-defined panels of i) conventional chemotherapies and/or ii) 
mitochondrially-targeted FDA-approved drugs (e.g., metformin and antibiotics). This would allow us to achieve the goals of personalized 
cancer treatment, by establishing the chemo-sensitivity profiles of mito-high CSCs in individual patients, leading to the prevention of tumor 
recurrence and metastasis, in multiple cancer types. Chemo-resistant “mito-high” CSCs could also be expanded by using 3D-spheroid 
cultures, possibly for biobanking and drug screening.
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ESA, CD133, KRT19) are not generally thought of 
as therapeutically druggable targets. In contrast, the 
discovery of mitochondrial mass as a biomarker of CSC 
activity, as detected using the MitoTracker probe, suggests 
that we could therapeutically target mitochondria to 
more effectively eradicate the CSC population. There 
are many potential targets within mitochondria that 
could be inhibited to improve cancer treatment. These 
include targeting mitochondrial control of apoptosis with 
inhibitors the BCL-2 family [62] or HSP90, which has 
been shown to be specifically expressed in cancer cell 
mitochondria, but not their normal counterparts [63, 64]. 
Specific targeting of upregulated metabolic pathways, such 
as fatty acid synthesis, glycolysis and OXPHOS have also 
been shown to have anti-cancer effects (reviewed in Ref 
[65]). As discussed above, mitochondrial biogenesis can 
be induced by the hyper-activation of numerous signaling 
pathways and oncogenes, such as mTOR and Myc, which 
can be inhibited using rapacycin analogues e.g. everolimus 
[66] or DCR-MYC, a novel siRNA-based therapeutic, 
designed to silence the MYC oncogene which is currently 
in Phase I clinical trials [67].
The “Endo-symbiotic Theory of Mitochondrial 
Evolution” suggests that mitochondria originally 
evolved from engulfed aerobic bacteria, over millions 
of years of adaptation [68, 69]. As such, antibiotics 
target mitochondria, and therefore this side effect could 
be exploited to target the increased mitochondrial mass 
within CSCs. Interestingly, several FDA-approved drugs/
antibiotics that target mitochondria have already been 
shown to eradicate CSC activity, such as OXPHOS 
inhibitors (metformin and pyrvinium pamoate) [70–73], 
a potassium ionophore (salinomycin) [74, 75] and known 
inhibitors of mitochondrial biogenesis and mitochondrial 
translation (the erythromycins, the tetracyclines and 
the glycylcyclines) [76, 77]. In fact, doxycycline and 
azithromycin have already shown significant efficacy in 
treatment-resistant cancer patients, with MALT lymphoma 
and non-small cell lung tumors, respectively [78–80].
The discovery that MitoTracker can identify a live 
population of cancer cells (mito-high) that are enriched 
for chemo-resistant cells may have a potential role in 
personalized medicine. For example the isolation of mito-
high cells from patient samples could be used to screen 
for sensitivity to current or new therapies, by measuring 
cell death, mammosphere formation, or by employing 
a simple colony survival assay (Figure 6). Mito-high 
cells could also be isolated for genomic and proteomic 
analyses. Detailed analysis of the transcriptome and the 
proteome of mito-high cells, as compared to the mito-low 
cell populations, could reveal specific pathways that mito-
high cells depend on for survival and maintenance. These 
specific pathways could then be targeted, to eliminate 
this chemo-resistant cell population. With further 
development, our new findings could have important 
clinical relevance for targeting CSCs, by improving 
sensitivity to chemotherapy and aiding in the discovery 
of new therapeutics that inhibit mitochondrial biogenesis 
in CSCs.
In summary, metabolic fractionation of cancer 
cell lines and primary metastatic breast cancer samples, 
identified a stem-like, mitochondrial-rich sub-population 
of tumor cells (Figure 7). CSCs with high mitochondrial 
mass showed an increased capacity for mammosphere 
formation, tumor initiation and were resistant to DNA-
damage induced by paclitaxel. Thus, these results provide 
a new mitochondrially-based model for understanding 
the molecular relationship between CSCs and chemo-
resistance.
MATERIALS AND METHODS
Cell lines and media
MCF7 and MDA MB 231 cell lines were purchased 
from ATCC and maintained in monolayer media—
DMEM, supplemented with 10% (v/v) fetal calf serum 
and 200 mM L-glutamine (Sigma). Mammosphere media 
consisted of DMEM/F12, phenol-red-free, supplemented 
with 1 × B27 without vitamin A (Gibco), plus 20 ng/ml 
human EGF (Milteny Biotech).
Human tumor tissues
Metastatic breast cancer sample were obtained from 
pleural effusions or ascites. Approval for these samples 
was granted by the Christie Medical Research and 
Biobank Ethics Committees. All patients provided written 
informed consent.
Flow-cytometry analysis and sorting
ALDEFLUOR activity
5 × 105 cells were re-suspended in 1 ml Assay buffer 
and 5 μl ALDEFLUOR reagent (Stem Cell Technologies) 
was added and mixed well. 0.5 ml of this cell suspension 
was transferred into a new tube with 5 μl of DEAB regent 
(Stem Cell Technologies). Tubes were incubated for 
30 mins at 37°C before centrifugation and re-suspension 
in Assay Buffer (0.5 ml) for FACS analysis (BD, LSR 
Fortessa). When combined with MitoTracker Deep-Red 
(Molecular Probes, 0.125 μl/ml), both were added before 
30 min incubation. Note the PDX model BB6RC50 was 
also co-stained with anti-mouse MHC Class I (H-2Kd) 
antibody conjugated with Pacific Blue (BioLegend, 
116616), to exclude mouse cells in the ALDH analysis.
Mitotracker staining
Exponentially dividing MCF7 and MDA 
MB 231 cells were trypsinized and re-suspended into a 
1 × 106 cell/ml solution in PBS. 0.125 μl/ml MitoTracker 
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Deep-Red (Molecular Probes) was added for 30 mins 
at 37°C before centrifugation and re-suspension in PBS 
for FACS analysis (BD, LSR Fortessa) or Sorting (BD, 
Aria III).
CSC cell surface markers
Exponentially dividing MDA MB 231 cells were 
trypsinized and re-suspended into a 1 × 106 cell/100 μl 
PBS. MitoTracker (0.125 μl/ml) was added to cell 
suspension for 30 mins at 37°C before centrifugation 
and re-suspension in 100 μl PBS and the addition of 
10 μl ESA-FITC (DAKO, BerEP4), 10 μl CD24-PE 
(Pharmingen) for 10 mins at 4°C before centrifugation 
and re-suspension in PBS for FACS analysis (BD, LSR 
Fortessa. All tubes were incubated with 1 μl/ml live/dead 
fixable violet cell stain (Molecular Probes) to exclude dead 
cells from FACS analysis and sorting.
Comet assay
Alkaline comet assays were modified from [33]. 
MDA MB 231 and MCF7 cells were FACS sorted for 
the 5% highest and lowest MitoTracker expressing cells. 
Cells were seeded into 24 well plates (2 × 104 cells) and 
treated with 0.1 μM paclitaxel for 24 h. Cell were them 
trypsinized and resuspended into 250 μl cell media; 750 μl 
of low melting point agarose (1% w/v in PBS, at 40°C) 
was added to the cell suspensions before pipetting on to a 
pre-agarose coated glass slide and a glass cover slip was 
placed on top. After 15 min at 4°C, slides were placed 
in lysis buffer (2.5 M NaCl, 1 mM EDTA, 10 mM Tris, 
10% DMSO, 1% Triton X-100, pH 10) and left at 4°C 
overnight. Slides were placed in alkaline solution (0.3 M 
NaOH, 1 mM EDTA, pH13) for 50 mins at 4°C and 
electrophoresed at 23 V for 50 mins (4°C). SYBRgold 
Figure 7: Understanding the relationship between mitochondrial mass, “stemness” and chemo-resistance in cancer 
cells. Our report suggests that high mitochondrial mass, quantified using live MitoTracker staining, is associated with a number of stem 
cell characteristics and biological functions including CSC markers ALDH+, ESA/CD24, large cell size, mammosphere formation in vitro, 
as well as tumor-initiating activity in vivo. Moreover, cells with high mitochondrial mass were preferentially resistant to paclitaxel during 
mammosphere formation and the comet assay (a marker DNA damage), when compared to low mitochondrial mass cells. Thus, we conclude 
that high mitochondrial mass can be used as a biomarker to isolate a sub-population of stem-like cancer cells that are chemo-resistant. This 
has important implications for better appreciating the role of tumor metabolic heterogeneity in driving chemo-resistance and treatment 
failure, via recurrence and metastasis.
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(Molecular Probes) was applied (1:10,000 in TE buffer, 
10 mM Tris-Cl, pH7.5, 1 mM EDTA) to stain the DNA. 
Comets were imaged (Zeiss Axiovert 200 M, x10 lens) 
and measured using OPENCOMET free software 29 for 
Image J (v1.3).
Isolation of breast cancer cells from primary 
samples and patient derived xenografts
Breast cancer cells were isolated from pleural 
effusions or ascites fluid from metastatic breast cancer 
patients (n = 4), using the following method. The acquired 
samples were centrifuged at 4°C for 10 min at 1000 × g, 
followed by resuspension in cold PBS. Red blood cells 
were removed using Lymphoprep™ (Axis-Shield) and 
subsequently leukocytes were removed with CD45-
negative magnetic sorting (Miltenyi Biotech), according 
to the manufacturer’s instructions. Metastatic human 
breast cancer samples were collected from patients at The 
Christie NHS Foundation Trust. All patients underwent 
fully informed consent, in accordance with local 
research ethics committee guidelines (05/Q1403/159 and 
05/Q1402/25). The PDX model BB6RC50 was generated 
from the subcutaneous injection of 1 million metastatic 
breast cancer cells into NOD scid gamma mice. Passage 2 
tumors were removed, dissected into 2–3-mm cubed 
pieces and then digested for 1–2 hours at 37°C in serum-
free Dulbecco’s modified Eagle Medium (DMEM;Gibco) 
containing × 1 collagenase/hyaluronidase (STEMCELL 
technologies) and penicillin (100 U/mL) – streptomycin 
(0.1 mg/mL; Sigma). The enzymatically digested tumor 
was then filtered through a sterile 40-μm mesh/sieve, to 
obtain a single-cell suspension and washed in cold PBS.
Mammosphere culture of breast cancer cells
Mammospheres were cultured as described [30]. In 
brief, single cells from MCF7 and MDA MD 231 cell lines 
or primary metastatic samples were seeded at 500 cells per 
cm2 on poly-HEMA-coated plates. Mammosphere forming 
efficiency (MFE) was calculated as follows: [(number of 
mammospheres formed (≥60 μm) ÷ by the number of cells 
seeded) × 100].
Tumor initiation and Extreme limiting 
dilution assay (ELDA)
MDA MB 231 cells were stained with MitoTracker 
and sorted into two populations; mito-low (lowest 
5% mitochondrial mass) and mito-high (highest 5% 
mitochondrial mass). Cells were then resuspended in 
1:1 solution of mammosphere media and growth factor 
reduced matrigel. NOD scid gamma (NSG) mice were 
then subcutaneously injected with 1, 5, 10 and 50 cells per 
flank (n = 3 mice per group) of mito-low and mito-high 
MDA MB 231 cells. Tumor size was measured bi-weekly 
(L × W × W/2) with calipers over 9 weeks (<100 μm = no 
tumor initiation). The tumor initiation rate from each 
population was then used to calculate tumor initiating cell 
frequency, using the extreme limiting dilution analysis 
calculation: http://bioinf.wehi.edu.au/software/elda/ [32].
Statistical analysis
In vitro data is represented as the mean ± standard 
error of the mean (SEM), taken over ≥3 independent 
experiments, with ≥3 technical replicates per experiment, 
unless otherwise stated. Statistical significance was 
measured using the analysis of variance (ANOVA) test 
with post-hoc dunetts multiple comparisons or t-test, 
using Graphpad prism. P ≤ 0.05 was considered significant 
and all statistical tests were two-sided. All statistics were 
carried out under the guidance of the Medical Statistics 
Department, Christie Hospital NHS Trust, UK.
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